Atterocor, Inc., a company developing a novel therapy for adrenal cancer, today announced the appointment of eight leading experts to its newly founded clinical advisory board. Atterocor convened the inaugural meeting of its clinical advisory board in conjunction with the 12th Annual European Network for the Study of Adrenal Tumours (ENS@T) Scientific Meeting, which was held Nov. 22-23, 2013 in Budapest. Atterocor is a supporting member of ENS@T.
Help employers find you! Check out all the jobs and post your resume.
